CliffBio
small molecule

NALOXONE HYDROCHLORIDE (AUTOINJECTOR)

NALOXONE HYDROCHLORIDE

Loss of exclusivityMay 2031latest FDA-listed patent expiry
CompanyKaleo →See this company's full patent-cliff portfolio

Drug detail

Brand nameNALOXONE HYDROCHLORIDE (AUTOINJECTOR)
Active ingredientNALOXONE HYDROCHLORIDE
Strength10MG/0.4ML (10MG/0.4ML)
Dosage formSOLUTION
RouteINTRAMUSCULAR, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalFebruary 2022
Marketing statusDISCN

Listed patents

PatentExpiresType
10143792May 2031use U-2476
10322239February 2031use U-1907
9474869February 2031product
8939943February 2031product
9022022February 2031product
9814838February 2031product

More from Kaleo

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.